VTVT
vs
S&P 500

Over the past 5 years, VTVT has underperformed S&P 500, delivering a return of -82% compared to the S&P 500's 81% growth.

Stocks Performance
VTVT vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
VTVT vs S&P 500

Performance Comparison
VTVT vs S&P 500

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
VTVT
vTv Therapeutics Inc
-18%
-7%
-23%
34%
-82%
-97%
-97%
S&P 500
Market Index
-4%
2%
5%
25%
81%
190%
394%

vTv Therapeutics Inc
Glance View

Market Cap
43.3m USD
Industry
Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 9 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

VTVT Intrinsic Value
5.9179 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

Back to Top